BI-RADS 4: What This Finding Means for Your Mammogram

A BI-RADS 4 finding on your mammogram means the radiologist spotted something suspicious enough to recommend a biopsy, but the chance it is cancer ranges widely, from as low as about 2% to as high as 95%, depending on the specific subcategory assigned. That enormous range is exactly why BI-RADS 4 is the single broadest category in the system and the one that generates the most confusion and anxiety. The subcategory your radiologist assigns, the imaging characteristics of the finding, and the biopsy results together determine what actually comes next.

What the BI-RADS System Is and Why Category 4 Stands Out

BI-RADS stands for Breast Imaging Reporting and Data System, a standardized way radiologists describe and classify mammogram findings so that every imaging center uses the same language. The system runs from category 0 (the images need more work) through category 6 (a known, biopsy-proven cancer). Categories 1 and 2 are normal or clearly benign. Category 3 is probably benign, with a recommendation for short-term follow-up. Category 5 is highly suggestive of cancer. Category 4 sits in the middle and covers a much wider probability of malignancy than any other category, spanning from just over 2% to just under 95%.¹ Because of that breadth, the category is split into three subcategories that give you and your doctor a much better sense of where things stand.

The Three Subcategories and What They Mean for You

BI-RADS 4A covers findings with a low suspicion of malignancy, defined as greater than 2% but no more than 10% likelihood of cancer. BI-RADS 4B covers intermediate suspicion, from above 10% to 50%. BI-RADS 4C covers high suspicion, from above 50% to just under 95%.² Those ranges are guideline benchmarks. In practice, the actual rates of cancer found at biopsy vary by study and population, but they track the same pattern: low in 4A, moderate in 4B, and high in 4C.

One study of nonpalpable lesions found that the positive predictive values for subcategories 4A, 4B, and 4C were roughly 20%, 42%, and 74%.³ Another study reported higher numbers: about 34% for 4A, 89% for 4B, and 97% for 4C, with 4C patients tending to be older and to have larger masses at presentation.⁴ A third study looking at a larger mixed cohort found an overall malignancy rate for all BI-RADS 4 lesions of about 35%, with subcategory-specific rates of roughly 18% for 4A, 59% for 4B, and 90% for 4C.⁵

The variation between studies reflects differences in patient populations, imaging modalities, and how tightly radiologists apply the subcategories. The bottom line is consistent, though: if you received a 4A classification, the odds are strongly in your favor that the finding is benign. At 4C, the suspicion is high enough that your medical team will be preparing you for the possibility of a cancer diagnosis.

What Imaging Features Make a Finding Look Suspicious

Radiologists do not assign BI-RADS 4 at random. Specific visual characteristics on the mammogram or ultrasound drive the classification. In ultrasound-evaluated lesions, an irregular shape carried a positive predictive value of about 66%, a spiculated margin about 80%, and a nonparallel orientation about 59%. On the flip side, features like an oval shape, well-defined borders, and parallel orientation were reassuring signs that made a benign result more likely.³ When the finding is an architectural distortion on a mammogram, the BI-RADS classification had a sensitivity of about 90% but a specificity of only about 43%, meaning it catches most cancers but also flags many benign areas.⁶

This is why you might hear your radiologist mention terms like “spiculated margins” or “irregular shape” when explaining why a biopsy is recommended. They are describing the visual clues that pushed the finding past the threshold of “probably benign” into “needs tissue sampling.”

Why a Biopsy Is the Next Step

For any BI-RADS 4 finding, regardless of subcategory, the standard recommendation is a tissue biopsy. Imaging alone cannot definitively tell benign from malignant. The good news is that nearly all biopsies done for BI-RADS 4 findings are percutaneous, meaning a needle is guided through the skin rather than requiring a surgical incision. These needle biopsies are faster, less invasive, and less expensive than surgical alternatives.⁷

The type of imaging used to guide the needle depends on how the finding was originally detected. If it was visible on ultrasound, an ultrasound-guided biopsy is typical. If it was seen only on a mammogram, stereotactic or tomosynthesis-guided biopsy may be used. Some findings are visible only on MRI and require MRI-guided biopsy.⁸ You do not usually get to choose the method; the imaging characteristics and the visibility of the lesion dictate which approach will get the most accurate sample.

What the Biopsy Results Can Show

Biopsy results generally fall into three buckets: benign, high-risk (sometimes called “borderline” or “atypical”), and malignant. The majority of BI-RADS 4 biopsies, especially in the 4A subcategory, come back benign. Common benign diagnoses include fibroadenomas (the most common benign breast tumors, found in about a quarter of women), fibrocystic changes, and other noncancerous conditions that do not require treatment.⁹

The trickier middle ground involves high-risk lesions, which are not cancer themselves but indicate an elevated future risk. The one that gets the most clinical attention is atypical ductal hyperplasia (ADH). When ADH shows up on a core needle biopsy, there is a risk that the small tissue sample missed nearby cancer cells. Estimates of this “upgrade” rate range from about 15% to 25%, with invasive cancer specifically found in roughly 3% of cases.¹⁰ Because of that risk, the standard recommendation has been surgical excision of the area for a more thorough pathological evaluation.

Recent research is refining this. When certain favorable conditions are met, such as removal of most of the calcifications during biopsy, involvement of fewer tissue structures, and no discordance between imaging and pathology, the chance of a missed cancer drops to under 5%. In carefully selected patients meeting these criteria, close observation instead of surgery is increasingly being considered.¹¹ One predictive model identified a subset of women with only about a 2% risk of upgrade, potentially sparing them an operation.¹²

The Concordance Check You Should Know About

After biopsy results come back, your radiologist performs a step that many patients never hear about: imaging-pathology concordance. This means comparing what the imaging looked like with what the tissue sample showed under a microscope. The question is whether the pathology result makes sense given the appearance of the finding on imaging. If a lesion looked highly suspicious on the mammogram but the biopsy came back as completely normal tissue, something may have gone wrong with the sample, and a repeat biopsy or surgical excision could be recommended.¹³

This step matters because sampling errors happen. A needle biopsy takes a small piece of a larger area, and occasionally the needle misses the most concerning part of the lesion. A systematic review of discordant cases found that when imaging and pathology results do not line up, repeat sampling or surgical excision rather than simply watching and waiting leads to better outcomes.¹⁴ If your doctor tells you the results are “concordant benign,” that is a strong reassurance that the biopsy accurately captured what was there.

Follow-Up After a Benign Biopsy Result

When a BI-RADS 4 biopsy comes back benign and the imaging and pathology results agree, you are not done entirely. The standard recommendation has been to return for a follow-up ultrasound about six months later, then annually for at least two years.¹⁵ The goal is to confirm the finding stays stable and does not grow or change in character.

That said, there is growing evidence that for truly concordant benign results, the first follow-up can safely be pushed to 12 months rather than six. Researchers have found that routine short-interval imaging under 12 months does not catch significantly more cancers in concordant cases and may add unnecessary cost and anxiety.¹⁵ Your doctor may still recommend the six-month check in select situations, but if they tell you to come back in a year, that is not a sign of neglect.

How Breast Density Complicates the Picture

If you have dense breasts, the path from BI-RADS 4 to a clear answer can be rockier. Mammography’s ability to detect cancer drops significantly in dense tissue. In extremely dense breasts, mammography’s sensitivity can fall to roughly 44%, compared to about 78% in heterogeneously dense breasts. Ultrasound holds up better in both categories, maintaining sensitivity around 84% to 86%.¹⁶

Dense tissue also creates more false alarms. Normal glandular tissue can mimic or hide suspicious findings on a mammogram, which means more women with dense breasts end up in the BI-RADS 4 category in the first place. Breast density is itself considered a risk factor for breast cancer and affects how sensitive the mammogram is.¹⁷ Many states in the U.S. now require that mammogram reports notify you of your breast density, specifically because it affects the reliability of the test. If you have very dense breasts and receive a BI-RADS 4 finding, your doctor may suggest supplemental imaging with ultrasound or MRI to get a clearer picture.

The Role of MRI in BI-RADS 4 Findings

Breast MRI is not routinely ordered for every BI-RADS 4 finding, but it can add useful information in certain cases. When suspicious lesions undergo contrast-enhanced MRI, the imaging can help stratify risk more precisely. Adding diffusion-weighted imaging on top of standard contrast-enhanced MRI slightly improves this risk stratification.¹⁸ MRI is most often brought in when the mammogram or ultrasound results are ambiguous, when the patient has dense breast tissue, or when there is a high-risk family history that warrants more thorough evaluation.

Anxiety Around the Biopsy Process

Receiving a BI-RADS 4 result is stressful, and the research confirms what you probably already know: the waiting period is hard. Studies have found clinically significant anxiety associated with the biopsy process itself, and this anxiety is higher when biopsies are performed the same day the recommendation is made, possibly because there is less time to mentally prepare.¹⁹

One factor that genuinely helps is good communication with the radiologist. A study measuring patient anxiety before and after biopsy found that better communication from the radiologist recommending the biopsy was linked to meaningfully lower prebiopsy anxiety. After the biopsy itself, anxiety dropped significantly in nearly all patients, and again, better communication with the radiologist performing the procedure was associated with lower postbiopsy anxiety even after accounting for each patient’s baseline stress level.²⁰ If you feel uninformed or rushed, asking your radiologist to walk you through what they see and what will happen during the biopsy is a reasonable and evidence-backed way to reduce your distress.

Reducing Unnecessary Biopsies With AI

Because most BI-RADS 4 biopsies come back benign, researchers have been working on ways to spare patients from procedures they do not need. Artificial intelligence tools trained on mammographic data are showing promise. One deep-learning decision support tool, called iBRISK, demonstrated the potential to safely eliminate up to half of biopsies for patients in the low or moderate probability groups while maintaining high sensitivity for detecting actual cancers.²¹

Comparisons between AI and radiologists working alone have found trade-offs. In one study, AI was slightly more accurate overall (about 90% versus 83% for the radiologist alone) and had a higher positive predictive value, meaning it was better at confirming that a suspicious-looking finding was indeed cancer. But radiologists still achieved higher sensitivity, meaning they were slightly better at catching every cancer even if it meant more false alarms.²² The emerging model is not AI replacing radiologists but AI working alongside them, helping refine which BI-RADS 4 findings truly need a biopsy and which can be safely monitored.

A related approach tested by expert radiologists involves raising the intervention threshold for lower-suspicion findings. In a pilot study, researchers explored requiring a higher estimated probability of cancer before recommending biopsy, substituting short-term follow-up for the lowest-risk cases. Depending on the threshold chosen, between about 22% and 56% of biopsies could have been avoided while missing very few invasive cancers.²³ These strategies are not yet standard practice, but they point to a future where fewer patients with benign findings undergo an invasive procedure.

The Financial Side of Follow-Up

The diagnostic workup following a screening mammogram can add up. Across the U.S. population, an estimated 1.6 million biopsies are performed annually in the follow-up period after screening. Mean costs for diagnostic mammograms ran about $349, ultrasounds about $132, and biopsies about $1,938. Altogether, annual diagnostic breast expenditures in the U.S. were estimated at roughly $7.9 billion.²⁴ Nearly half of patients who had an initial diagnostic procedure went on to have a second one, and about a fifth had a third. For patients who receive a BI-RADS 4 finding and then face a biopsy plus follow-up imaging over two or more years, the total out-of-pocket burden can be substantial depending on insurance coverage. Asking your insurance provider or the imaging facility about estimated costs before each step is practical advice that many patients overlook.

Disparities in Getting to the Biopsy

Not everyone gets to the biopsy at the same speed. Research has found that after an abnormal mammogram, Black women waited a median of 20 days and Hispanic women 21 days for diagnostic follow-up, compared with 14 days for non-Hispanic white women. These gaps persisted even after accounting for age, BI-RADS category, insurance status, and income.²⁵ A week’s difference may sound small, but when you are waiting to find out whether a suspicious finding is cancer, every day feels long, and longer delays can occasionally mean a diagnosis at a later stage. If you feel your follow-up is being delayed, advocating with your referring physician or asking about patient navigation programs at your imaging center can help close that gap.